Recognized at the Asia Pacific Biopharma Excellence Awards

Showcased CDO Technology Platforms Including S-Hycon

Samsung Biologics announced on March 12 that it participated in the Asia Biopharmaceutical Manufacturing Conference (BMA 2026), a global biopharmaceutical technology conference.


Heonchang Lim, Head of Formulation Development Group at Samsung Biologics (right), is receiving an award on behalf of the company at the Asia Pacific Biopharma Excellence Awards (ABEA 2026) held in Singapore on the 11th (local time). Samsung Biologics

Heonchang Lim, Head of Formulation Development Group at Samsung Biologics (right), is receiving an award on behalf of the company at the Asia Pacific Biopharma Excellence Awards (ABEA 2026) held in Singapore on the 11th (local time). Samsung Biologics

View original image

At this event, Samsung Biologics promoted its strong contract development (CDO) capabilities, including high-concentration formulation drug development, and further demonstrated its competitiveness in contract manufacturing (CMO) by receiving an award at the Asia Pacific Biopharma Excellence Awards (ABEA 2026).


The ABEA is an award presented to companies in the Asia-Pacific region that have demonstrated outstanding achievements over the past year in areas such as bioprocessing, logistics, supply chain management, clinical trial expertise, corporate organization, and technology.


Celebrating its 13th year, the BMA is the largest biopharmaceutical technology event in Asia, sponsored by the global pharmaceutical and biotech consulting firm IMAPAC. This year’s conference was held in Singapore over two days, March 11 and 12, with more than 500 companies and over 1,200 participants in attendance.


At the conference, on the afternoon of March 11, Samsung Biologics showcased its CDO technology by presenting on its high-concentration formulation development platform, S-Hycon. Heonchang Lim, Head of Formulation Development Group at the CDO Development Center, delivered the presentation, sharing key development cases, challenges, and solutions related to S-Hycon, as well as introducing Samsung Biologics’ major CDO services.


Launched in 2024, S-Hycon is a platform that leverages Samsung Biologics’ extensive experience in formulation development to support clients in the development of high-concentration formulation substances. The company explained that high-concentration formulation drugs reduce the burden of administration for patients and can lower storage and transport costs, which has led to increasing market demand.



Currently, Samsung Biologics owns nine CDO-related technology platforms, including S-Hycon, the DevelopPick platform for evaluating substance development feasibility, the proprietary cell line platform S-CHOice, and the candidate molecule transient expression platform S-CHOgiant.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing